title: NGAL is a precocious marker of therapeutic response.
abstract: NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohn's disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
authors.affiliation: University of Messina, Department of Internal Medicine, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Cernaro
authors.forename: Davide
authors.initials: D
authors.lastname: Bolignano
authors.forename: Valentina
authors.initials: V
authors.lastname: Donato
authors.forename: Antonio
authors.initials: A
authors.lastname: Lacquaniti
authors.forename: Antoine
authors.initials: A
authors.lastname: Buemi
authors.forename: Eleonora
authors.initials: E
authors.lastname: Crascì
authors.forename: Silvia
authors.initials: S
authors.lastname: Lucisano
authors.forename: Michele
authors.initials: M
authors.lastname: Buemi
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002908:Chronic Disease; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism*; D000071068:Lipocalin-2; D054834:Lipocalins / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins